Mateon Therapeutics Inc. said that, so far, five of 21 people with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome have achieved complete remissions after being treated with its vascular disrupting agent, Oxi-4503, in combination with cytarabine during a phase Ib dose-escalation study.